Development and in vitro characterization of recombinant vaccinia viruses expressing bovine leukemia virus gp51 in combination with bovine IL4 or IL12

被引:8
|
作者
Von Beust, BR [1 ]
Brown, WC
Estes, DM
Zarlenga, DS
McElwain, TF
Palmer, GH
机构
[1] Washington State Univ, Coll Vet Med, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA
[2] Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA
[3] ARS, Immunobiol & Dis Resistance Lab, USDA, Beltsville, MD 20705 USA
关键词
vaccinia virus; bovine IL12; bovine IL4;
D O I
10.1016/S0264-410X(98)00208-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Type 1 and type 2 immune responses are modulated by IL12 or IL4, respectively, at the time of lymphocyte priming. Importantly, type 1 responses have been associated with resistance to retroviral infection in mice, humans, and ruminants. Specifically, vaccination of sheep with vaccinia virus expressing bovine leukemia virus (BLV) gp51 resulted in protective immunity with the characteristics of a type I response, whereas vaccination of cattle resulted in a non-protective type 2 response. In order to test the hypothesis that cattle inoculated with BLV gp51 and IL12 will respond with a type 1 response, a recombinant vaccinia virus expressing BLV gp51 together with bovine IL12 was developed and characterized in vitro. For induction of type 2 responses a recombinant vaccinia virus expressing gp5I with bovine IL4 was similarly constructed and characterized. In this study recombinant cassettes were developed containing either the BLVenv gene alone or in combination with bovine IL4 or the two genes, p35 and p40, encoding bovine IL12. Correct alignment with p7.5 or p11 vaccinia promoters and orientation was confirmed by complete sequencing. Recombinant vaccinia viruses were generated by homologous recombination, selected based on large plaque formation due to reconstitution of the vp37 gene, and structurally confirmed by Southern blotting. Transcription of recombinant BLVenv, bovine IL4, p35 and p40 was demonstrated by RT-PCR. Expression of BLVenv gp51 protein and bovine IL4 was shown by immunofluorescence and immunoblotting. Biologically active bovine IL4 expressed by vaccinia virus stimulated lymphoblast proliferation, B lymphocyte proliferation in the presence of CD40L, and inhibited IFN gamma, secretion from PHA activated PBMC in a dose dependent fashion. Finally, bovine IL12 expression and biological function was confirmed by dose dependent induction of IFN gamma secretion by PHA activated PBMC and the moderate enhancement of lymphoblast proliferation. In conclusion, bovine IL12 and IL4 expressed by recombinant vaccinia virus in vitro clearly exhibited type 1-type 2 modulating properties. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:384 / 395
页数:12
相关论文
共 14 条
  • [11] PROTECTION OF SHEEP AGAINST BOVINE LEUKEMIA-VIRUS (BLV) INFECTION BY VACCINATION WITH RECOMBINANT VACCINIA VIRUSES EXPRESSING BLV ENVELOPE GLYCOPROTEINS - CORRELATION OF PROTECTION WITH CD4 T-CELL RESPONSE TO GP51-PEPTIDE 51-70
    GATEI, MH
    NAIF, HM
    KUMAR, S
    BOYLE, DB
    DANIEL, RCW
    GOOD, MF
    LAVIN, MF
    JOURNAL OF VIROLOGY, 1993, 67 (04) : 1803 - 1810
  • [12] Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12
    Mackova, J
    Kutinova, L
    Hainz, P
    Krystofova, J
    Sroller, V
    Otahal, P
    Gabriel, P
    Nemeckova, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 24 (06) : 1581 - 1588
  • [13] Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions
    Taylor, G
    Thomas, LH
    Furze, JM
    Cook, RS
    Wyld, SG
    Lerch, R
    Hardy, R
    Wertz, GW
    JOURNAL OF GENERAL VIROLOGY, 1997, 78 : 3195 - 3206
  • [14] The combination of DNA vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK
    Tapia, E
    Pérez-Jiménez, E
    López-Fuertes, L
    Gonzalo, R
    Gherardi, MM
    Esteban, M
    MICROBES AND INFECTION, 2003, 5 (02) : 73 - 84